Tag: large-cap
Cigna Group Stock Analysis: Buy or Sell? Valuation, Cash Flow & Margin
The Cigna Group (CI) is rated Hold as its durable cash generation offsets a post-divestiture earnings base that still needs to prove itself. The 9.0% FCF yield and 1.72x net debt to EBITDA support the stock, but margin improvement remains the key test.
Teva Pharmaceutical Stock Analysis: Buy or Sell? Valuation, Growth & Margins
Teva Pharmaceutical Industries Ltd. (TEVA) is rated Hold as the stock has already rerated on an earnings recovery, while revenue still faces generic pricing pressure. The business generates solid cash flow and strong EBITDA margins, but execution on branded growth and the AUSTEDO pricing reset remain key risks.
Newmont Corporation Stock Analysis: Buy or Sell? Valuation, Gold Prices & FCF
Newmont Corporation (NEM) is rated Hold as its stock already discounts a strong gold-price backdrop. The balance sheet is solid and free cash flow is strong, but downside grows if bullion normalizes and margins compress.
Omnicom Stock Analysis: Buy or Sell? Valuation, Leverage & Margins
Omnicom Group Inc. (OMC) is rated Hold as merger-driven scale is offset by thin margins and elevated debt. The 22.0% free cash flow yield supports the stock, but integration execution and client concentration remain key risks.
Pan American Silver Stock Analysis: Buy or Sell? Valuation & Margins
Pan American Silver (PAAS) is rated Hold as strong margins and a solid balance sheet are already reflected in the share price. Its 8.7x forward P/E and 7.0 PEG ratio leave limited room for disappointment if growth normalizes.
Honeywell Stock Analysis: Buy or Sell? Valuation, Margins & Spin-Off
Honeywell International Inc. (HON) is rated Hold as solid margins and cash flow are balanced by modest growth and a rich valuation. The Aerospace spin-off could clarify the story, but leverage and reacceleration still need to improve before a stronger rerating looks likely.
SAP Stock Analysis: Valuation, Cloud Migration, Margins & Growth
SAP (SAP) is rated Hold as the company continues to generate strong margins and free cash flow, but the shares already reflect much of that quality. Revenue and EBITDA growth are improving, yet valuation looks fair for a mature enterprise software franchise.
Boston Scientific Stock Analysis: Valuation, Reimbursement Risk, Cash Flow & Growth
Boston Scientific (BSX) earns a Buy rating on double-digit revenue growth, expanding EBITDA, and improving free cash flow. The key question is whether management can sustain execution while navigating reimbursement pressure and acquisition-led capital deployment.
Intuitive Surgical Stock Analysis: Valuation, Procedure Growth, China Risk & Cash Flow
Intuitive Surgical (ISRG) earns a HOLD rating as its dominant installed base and recurring revenue continue to support strong cash generation. However, the stock already prices in durable execution at a rich valuation, with China tender delays and pricing pressure clouding near-term upside.
General Electric Stock Analysis: Valuation, Margins, Leverage & Cash Flow
General Electric (GE) earns a HOLD rating as strong margins and cash generation are offset by a premium valuation. The company’s 40.4x trailing P/E and 31.4x EV/EBITDA leave little room for execution misses, especially with elevated leverage and a thin liquidity cushion.